Clinical Trials
4
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 52
- Registration Number
- NCT05517980
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 24
- Registration Number
- NCT05504187
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 80
- Registration Number
- NCT05490017
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT05476887
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, China
🇨🇳Chinese Academy of Medical Sciences Peking Union Medical College - Institute of Hematology Blood Diseases Hospital, Tianjin, China
News
No news found